PL373626A1 - Leczenie zaburzeń centralnego układu nerwowego - Google Patents
Leczenie zaburzeń centralnego układu nerwowegoInfo
- Publication number
- PL373626A1 PL373626A1 PL02373626A PL37362602A PL373626A1 PL 373626 A1 PL373626 A1 PL 373626A1 PL 02373626 A PL02373626 A PL 02373626A PL 37362602 A PL37362602 A PL 37362602A PL 373626 A1 PL373626 A1 PL 373626A1
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- nervous system
- central nervous
- system disorders
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/942,253 US20030082191A1 (en) | 2001-08-29 | 2001-08-29 | Treatment for central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL373626A1 true PL373626A1 (pl) | 2005-09-05 |
Family
ID=25477805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02373626A PL373626A1 (pl) | 2001-08-29 | 2002-08-27 | Leczenie zaburzeń centralnego układu nerwowego |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20030082191A1 (pl) |
| EP (1) | EP1434801A4 (pl) |
| JP (1) | JP2005504779A (pl) |
| CA (1) | CA2458799A1 (pl) |
| MX (1) | MXPA04001940A (pl) |
| PL (1) | PL373626A1 (pl) |
| WO (1) | WO2003020212A2 (pl) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| US20030082191A1 (en) * | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| GB0404187D0 (en) * | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
| US7625560B2 (en) | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
| CA2589860A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| MX2008001538A (es) * | 2005-08-02 | 2008-04-04 | Lexicon Pharmaceuticals Inc | Aril piridinas y metodos para su uso. |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| CA2632822C (en) | 2005-12-12 | 2018-08-28 | Ruth Greferath | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| PL2468770T3 (pl) | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| DK2104682T3 (en) | 2007-01-11 | 2017-01-16 | Michael Bacher | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| EP2586795B1 (en) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| EP2650308A3 (en) * | 2007-10-05 | 2014-11-12 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2261254A3 (en) | 2007-12-21 | 2011-04-13 | Amgen, Inc | Anti-amyloid antibodies and uses thereof |
| ES2767973T3 (es) * | 2008-02-29 | 2020-06-19 | Lantheus Medical Imaging Inc | Agentes de contraste para aplicaciones que comprenden formación de imágenes de perfusión |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| BRPI1011384A2 (pt) | 2009-02-23 | 2016-03-15 | Cytomx Therapeutics Inc | pro-proteinas e seus metodos de uso |
| KR101709372B1 (ko) | 2010-02-08 | 2017-02-22 | 랜티우스 메디컬 이메징, 인크. | 조영제 및 이의 중간체를 합성하는 방법 및 장치 |
| MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| EP3849410A4 (en) | 2018-09-14 | 2022-11-02 | Neuroenhancement Lab, LLC | SYSTEM AND METHODS FOR ENHANCEMENT OF SLEEP |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| WO2022169211A1 (ko) * | 2021-02-03 | 2022-08-11 | 한양대학교 산학협력단 | 베타아밀로이드를 포함하는 만성통증 질환 예방 또는 치료용 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5004697A (en) * | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5231000A (en) * | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
| US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
| US5260308A (en) * | 1991-11-06 | 1993-11-09 | Mayo Foundation For Medical Education And Research | Method to increase permeability of the blood-nerve/brain barriers to proteins |
| ES2173130T3 (es) * | 1993-10-20 | 2002-10-16 | Univ Duke | Metodo de fijacion de material al peptido beta-amiloide. |
| US5604198A (en) * | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
| JPH11514333A (ja) * | 1995-03-14 | 1999-12-07 | プレーシス ファーマスーティカルズ インコーポレイテッド | アミロイドの凝集の調節剤 |
| US5670477A (en) * | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| AU6266896A (en) * | 1995-06-07 | 1996-12-30 | Eukarion, Inc. | Transvacular and intracellular delivery of lipidized protein s |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| JP3422740B2 (ja) * | 2000-01-26 | 2003-06-30 | 旭ファイバーグラス株式会社 | サンドイッチ構造体用ハニカム芯材の製造方法 |
| AU2001249795A1 (en) * | 2000-04-04 | 2001-10-15 | Mayo Foundation For Medical Education And Research | Methods for detecting plaques in vivo |
| US7371365B2 (en) * | 2000-04-04 | 2008-05-13 | Mayo Foundation For Medical Education And Research | Methods for detecting parenchymal plaques in vivo |
| PT1346041E (pt) * | 2000-11-27 | 2007-06-05 | Praecis Pharm Inc | Agentes terapêuticos e métodos para a sua utilização no tratamento de uma doença amiloidogénica. |
| US20030082191A1 (en) * | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
-
2001
- 2001-08-29 US US09/942,253 patent/US20030082191A1/en not_active Abandoned
-
2002
- 2002-08-27 JP JP2003524526A patent/JP2005504779A/ja not_active Withdrawn
- 2002-08-27 MX MXPA04001940A patent/MXPA04001940A/es not_active Application Discontinuation
- 2002-08-27 PL PL02373626A patent/PL373626A1/pl not_active Application Discontinuation
- 2002-08-27 EP EP02761522A patent/EP1434801A4/en not_active Withdrawn
- 2002-08-27 WO PCT/US2002/027291 patent/WO2003020212A2/en not_active Ceased
- 2002-08-27 CA CA002458799A patent/CA2458799A1/en not_active Abandoned
-
2004
- 2004-03-09 US US10/796,522 patent/US20040142872A1/en not_active Abandoned
-
2009
- 2009-08-31 US US12/550,944 patent/US7988969B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003020212A3 (en) | 2004-02-19 |
| EP1434801A2 (en) | 2004-07-07 |
| US20090324492A1 (en) | 2009-12-31 |
| EP1434801A4 (en) | 2007-12-19 |
| JP2005504779A (ja) | 2005-02-17 |
| US7988969B2 (en) | 2011-08-02 |
| US20030082191A1 (en) | 2003-05-01 |
| MXPA04001940A (es) | 2004-07-23 |
| CA2458799A1 (en) | 2003-03-13 |
| US20040142872A1 (en) | 2004-07-22 |
| WO2003020212A2 (en) | 2003-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL373626A1 (pl) | Leczenie zaburzeń centralnego układu nerwowego | |
| PT2266594E (pt) | Vegf para utilização no tratamento de distúrbios do sistema nervoso central | |
| AU2003249983A8 (en) | Piperidines useful for the treatment of central nervous system disorders | |
| IL176581A0 (en) | Immunomodulatory compounds for the treatment of central nervous system disorders | |
| PL372425A1 (pl) | Pochodne III dihydrobenzodiazepin-2-onu | |
| GB0007193D0 (en) | Treatment of movrmrnt disorders | |
| IL175055A0 (en) | Combinations useful for the treatment of neuronal disorders | |
| EP1328186A4 (en) | METHODS OF TREATING VARIOUS EYES DISEASES | |
| WO2002030409A8 (en) | Methods for the treatment of a traumatic central nervous system injury | |
| AU2002356525A1 (en) | Substituted amines for the treatment of neurological disorders | |
| IL161267A0 (en) | Combinations for the treatment of immunoinflammatory disorders | |
| HUP0501017A3 (en) | Methods and compositions for treatment of central nervous system disorders | |
| IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
| EP1476147A4 (en) | METHODS OF TREATING VIEW DISORDERS | |
| PL368556A1 (pl) | Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2 | |
| MXPA03006607A (es) | Metodo combinado para tratar trastornos dependientes de hormonas. | |
| IL163993A0 (en) | Method for treating cognitive disorders | |
| IL170710A0 (en) | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | |
| MXPA03004190A (es) | Tratamiento de trastornos de ansiedad. | |
| IL162053A0 (en) | Method for the treatment of bone disorders | |
| GB0127384D0 (en) | Well treatment system | |
| SI1468686T1 (sl) | S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj | |
| GB0010496D0 (en) | Treatment of conditions of the central nervous system | |
| AU2003228813A8 (en) | Methods for treating neuronal disorders | |
| ZA200504565B (en) | 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |